News

Video

Approaches to Sequencing Therapies for HER2+ mBC

Author(s):

Jane L. Meisel, MD

Jane Meisel, MD, describes a personalized approach to later lines of treatment for HER2+ metastatic breast cancer, explaining the importance of considering patient priorities and individual circumstances.

Related Videos
2 experts are featured in this series.
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Related Content
Felipe Batalini, MD, of Mayo Clinic
December 26th 2024

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Lasofoxifene in Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 19th 2024

Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 16th 2024

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

Breast cancer / stock.adobe.com
December 16th 2024

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer